Tuesday, the FDA granted an emergency use nod to Novavax Inc's (NASDAQ: NVAX) COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.
B. Riley says today's authorization comes timely as the Street's bearish perception of overall COVID-19 vaccine demand. The pace of COVID-19 hospitalizations and emergency room visits has recently moderated after an initial spike in late August.
B. Riley says that growing awareness among the general population to drive protection of more vulnerable parts of society could drive wider adoption.
Today's availability of a non-mRNA protein-based alternative, with a ...